
This three-way crossover study will inform design of pivotal Phase 3 trials Top line ...

Development programs remain on track accompanied by continued strong fiscal management Conference call begins ...

MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue ...
Click to continue to site. Closing